HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Bio-Thera Solutions (688177.CH) - What's Next for Bio-Thera After R&D Setbacks and Years of Losses?

Pre-IPO Acotec Scientific Holdings - First-Mover Advantage Together with Challenges

Industry Report - Insights on China Biological Drug Market

A Different Angle - RemeGen Vs Akeso (Insights on Valuation)

Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%

Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>Last week, <a href="https://www.smartkarma.com/entities/remegen-co-ltd" target="_blank" data-smartkarma-citation="entities:29191:1" rel="noopener">Remegen Co Ltd (9995 HK)</a>'s core product RC18 has received conditional marketing approval in China for the treatment of SLE. RC18 is the first domestic innovative drug for the treatment of SLE approved for marketing in China in more than 60 years, with excellent therapeutic effect and is expected to fill the treatment gap. In addition, the Company officially launched its A-share IPO plan and is expected to list on the SSE STAR Market. The good news was also reflected in the stock price, in the last three trading days, the stock price of RemeGen increased by nearly 25%. </p>

Last week, Remegen Co Ltd (9995 HK)'s core product RC18 has received conditional marketing approval in China for the treatment of SLE. RC18 is the first domestic innovative drug for the treatment of SLE approved for marketing in China in more than 60 years, with excellent therapeutic effect and is expected to fill the treatment gap. In addition, the Company officially launched its A-share IPO plan and is expected to list on the SSE STAR Market. The good news was also reflected in the stock price, in the last three trading days, the stock price of RemeGen increased by nearly 25%. 

Remegen Co Ltd (9995.HK) - Commercialized RC18 + IPO On SSE STAR Market = New Chapter & Challenges